Q BioMed Inc.

Welcome to Q BioMed Inc. We are a biomedical acceleration and development company.

[Q BioMed Inc. @QBioMed]

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC. $QBIO #QBIO

https://t.co/cS4m2ox6EF

[Q BioMed Inc. @QBioMed]

$QBIO PROVIDES SHAREHOLDER UPDATE

Focus on Portfolio Monetization and Roll-up Strategy

https://t.co/16KPCdJQyF

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed reports Strontium89 sales revenue surge in shareholder update https://t.co/dYVmwkbE7k @QBioMed #QBIO

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed Inc. Provides Update to Shareholders https://t.co/Ll8LYZyJb3

[Q BioMed Inc. @QBioMed]

$QBIO welcomes study that highlights the safety and efficacy of Uttroside-B chemotherapeutic

https://t.co/Ne6EH0R6GY

[Proactive USA @proactive_NA]

$QBIO Q BioMed says new publication shows superior safety and efficacy of Uttroside-B versus FDA approved drug Sorafenib https://t.co/xC2U7q9wqf @QBioMed #QBIO

[Q BioMed Inc. @QBioMed]

Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer

https://t.co/4r1gsB6fJj

$QBIO

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets https://t.co/3BmB2YN97j @QBioMed #QBIO

[Q BioMed Inc. @QBioMed]

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets $QBIO

https://t.co/21DsPZJo5H

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver #Cancer https://t.co/kHHHoKDjCB @QBioMed #QBIO

[Q BioMed Inc. @QBioMed]

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer

https://t.co/OLQg6hwZLi

$QBIO

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed announces initial $500,000 order for Strontium89 injections in China https://t.co/nejznirG0R @QBioMed #QBIO

[Q BioMed Inc. @QBioMed]

Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market $QBIO

https://t.co/kuLiw7d4xh

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed outlines strategic direction and goals for 2022 https://t.co/jZ6bUsOrTx @QBioMed #QBIO

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed outlines strategic direction and goals for 2022 https://t.co/uD4T7ONxSc @QBioMed #QBIO

[Q BioMed Inc. @QBioMed]

Q BioMed Outlines Strategic Direction for 2022

Revenue Grows, Monetization Focus

$QBIO #QBIO

https://t.co/agwpZYRof7

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed Inc recaps 2021 achievements, and expands on progress expected from pipeline in 2022 https://t.co/WfG285EZKt @QBioMed #QBIO

[Q BioMed Inc. @QBioMed]

Revenue up 600% in 2021 and 100% in Q4
#NASDAQ Listing Expected in Jan 2022

https://t.co/2oJld9YZ0f

$QBIO #QBIO

[Q BioMed Inc. @QBioMed]

Strontium89 (Strontium Chloride Sr-89 Injection, USP) is the only approved radiotherapy currently available in the U.S. indicated for metastatic cancer bone pain palliation. $QBIO #Cancer

[Q BioMed Inc. @QBioMed]

$QBIO Q BioMed to forms partnership with EVERSANA to help commercialize Strontium89 https://t.co/lJwb1viTMF @QBioMed #QBIO #Cancer